Amen, 2022 - Google Patents
Isolation and characterization of human monoclonal antibodies blocking Plasmodium falciparum transmissionAmen, 2022
View PDF- Document ID
- 7427386219436247834
- Author
- Amen A
- Publication year
External Links
Snippet
Among people naturally exposed to Plasmodium falciparum (Pf) in endemic areas some naturally develop antibodies that are capable of inhibiting the development of the parasites in the mosquito, thus reducing or blocking further transmission to human. Although a few Pf …
- 230000005540 biological transmission 0 title abstract 7
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goh et al. | Vaccination with sporozoites: models and correlates of protection | |
| JP4475949B2 (en) | Recombinant anti-malarial antibody | |
| US20240067706A1 (en) | Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof | |
| Opi et al. | Multi-functional antibody profiling for malaria vaccine development and evaluation | |
| JP2005509410A6 (en) | Recombinant anti-malarial antibody | |
| US8765145B2 (en) | LSA-5 liver stage and blood stage antigen of Plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria | |
| Yoo et al. | Targeting Bottlenecks in Malaria Transmission: Antibody‐Epitope Descriptions Guide the Design of Next‐Generation Biomedical Interventions | |
| US20110002916A1 (en) | Plasmodium falciparum antigens and their vaccine and diagnostic applications | |
| US20070098738A1 (en) | MSP-3-like family of genes | |
| Amen | Isolation and characterization of human monoclonal antibodies blocking Plasmodium falciparum transmission | |
| JP2019502749A (en) | Immunoassemblyin (IA) protein complex | |
| Vukovic et al. | Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge | |
| US20240181026A1 (en) | Immunogenic compositions | |
| Matondo et al. | A VAR2CSA: CSP conjugate capable of inducing dual specificity antibody responses | |
| Bilsborough et al. | Fine epitope specificity of antibodies to region II of the Plasmodiumvivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites | |
| Venkatesh | DESIGNING mRNA BASED MULTISTAGE VACCINE FOR MALARIA | |
| Martin et al. | Malaria vaccines in clinical development: Introduction and recombinant/subunit approaches | |
| Mo et al. | NIAID meeting report: improving malaria vaccine strategies through the application of immunological principles | |
| Mitran | Investigation of the immunological cross-reactivity between Plasmodium vivax Duffy Binding Protein and Plasmodium falciparum VAR2CSA for vaccine development | |
| Rawlinson | Towards an effective vaccine against Plasmodium vivax malaria | |
| MUKIIRI | BIOENGINEERING OF PLASMODIUM FALCIPARUM SPECIFIC MONOCLONAL ANTIBODIES FOR ENHANCED NEUTROPHIL FUNCTION | |
| Williams | Investigation of the Plasmodium falciparum RH5-Interacting Protein (PfRIPR) as a blood-stage malaria vaccine target | |
| Partey | Understanding the Acquisition and Kinetics of Naturally Acquired Immunity to Pfrh5 Complex Proteins in Malaria | |
| Jairoce | Understanding the immunogenicity of RTS, S/AS0 vaccination in African children: antigen glycosylation, booster dose and off-target antibody responses | |
| Elias | Analysis of b cell responses to blood-stage malaria antigens in humans following immunization with candidate vaccines and controlled human malaria infection |